Table 2.
Susceptibility of VV Δ F2L-gfp to selected thymidine analogs and cidofovir.
Compound Name | VV Δ F2L-gfp (EC50, μM)a | VV WR wt (EC50, μM) |
IDU | 2.5 ± 0.9 | 2.4 ± 0.6 |
N-MCT | 6.2 ± 3.5 | 12 ± 1.6 |
PFT3 | 2.0 ± 0.6 | 2.4 ± 0.4 |
PFT4 | 2.3 ± 1.1 | 2.5 ± 0.1 |
CDV | 11 ± 4.2 | 10 ± 0.3 |
a. Concentration required to reduce plaque formation by 50%. Values shown are the average of duplicate determinations with the standard deviations shown.